))
AI for Drug Discovery and Longevity, w/ Rejuve CEOs Kennedy Schaal and Jasmine Smith
Manage episode 382905686 series 3503527
Innhold levert av Jeff Wilser. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Jeff Wilser eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
The most important, wide-reaching, and profound use case for AI might just be drug discovery. Normally it takes YEARS for scientists to develop drugs; AI can slash the timeline.
Kennedy Schaal is the CEO of Rejuve Bio, a startup that’s harnessing AI for faster drug discovery. And Jasmine Smith is the CEO of Rejuve AI, its sister company, which is racing to build a data-set that’s more equitable and inclusive and reflective of all humanity, with an end game of extending our longevity.
Kennedy and Jasmine discuss the current problems with drug discovery, how AI can help, and how AI can be especially impactful for more “niche diseases” that wouldn’t normally provide enough profit for Pharma companies to invest in.
Conversation with Rejuve Bio CEO Kennedy Schaal at (3:00).
Conversation with Rejuve AI CEO Jasmine Smith at (40:30).
Rejuve Biotech:
https://www.rejuve.bio
Rejuve AI:
https://www.rejuve.ai
Stay Connected:
• 🐦 Twitter/X
https://x.com/jeffwilser
• 💼 LinkedIn
https://www.linkedin.com/in/jeffwilser/
• 🖥️ JeffWilser.com
www.JeffWilser.com
🎧 Subscribe to AI-Curious:
• Apple Podcasts
https://podcasts.apple.com/us/podcast/ai-curious-with-jeff-wilser/id1703130308
• Spotify
https://open.spotify.com/show/70a9Xbhu5XQ47YOgVTE44Q?si=c31e2c02d8b64f1b
• YouTube Channel
https://www.youtube.com/@jeffwilser
72 episoder
Del
